Gene Therapy Delivering Defensin Peptide Prevents Infection-Related Preterm Birth in Mice
Delivering the human β-defensin-3 gene to the cervix of pregnant mice significantly reduced bacterial ascent into the uterus and increased live births.
Quick Facts
What This Study Found
Cervical gene delivery of HBD3 significantly reduced uterine bacterial bioluminescence and increased the number of live-born pups compared to controls in an ascending infection model.
Key Numbers
40% of preterm births infection-related; significant reduction in uterine bacteria at 24h; significant increase in live pups
How They Did This
AAV8 vector with HBD3 gene administered intravaginally to pregnant mice at E13.5, E. coli K1 infection induced at E16.5, bioluminescence imaging for bacterial tracking.
Why This Research Matters
Preterm birth from ascending infection is a major cause of neonatal mortality. Augmenting the cervix's natural antimicrobial peptide defenses could prevent infections without antibiotics.
The Bigger Picture
This proof-of-concept demonstrates that boosting natural antimicrobial peptide production at the cervical barrier could prevent infection-related preterm birth, a leading cause of neonatal death worldwide.
What This Study Doesn't Tell Us
Mouse model may not translate to human pregnancy. Single bacterial species tested. Long-term safety of viral vector delivery during pregnancy unknown.
Questions This Raises
- ?Could this approach work in humans with high-risk pregnancies?
- ?Would non-viral delivery methods be safer for pregnant women?
- ?Does HBD3 gene therapy affect the normal vaginal microbiome?
Trust & Context
- Key Stat:
- More live pups HBD3 gene therapy in pregnant mice significantly increased live births after ascending bacterial infection
- Evidence Grade:
- Animal study providing proof-of-concept. Promising results but far from clinical application.
- Study Age:
- Published in 2020. Gene therapy approaches for antimicrobial peptide delivery continue to be explored.
- Original Title:
- Cervical Gene Delivery of the Antimicrobial Peptide, Human β-Defensin (HBD)-3, in a Mouse Model of Ascending Infection-Related Preterm Birth.
- Published In:
- Frontiers in immunology, 11, 106 (2020)
- Authors:
- Suff, Natalie, Karda, Rajvinder, Diaz, Juan Antinao, Ng, Joanne, Baruteau, Julien, Perocheau, Dany, Taylor, Peter W, Alber, Dagmar, Buckley, Suzanne M K, Bajaj-Elliott, Mona, Waddington, Simon N, Peebles, Donald
- Database ID:
- RPEP-05150
Evidence Hierarchy
Frequently Asked Questions
How could antimicrobial peptides prevent preterm birth?
Many preterm births are caused by bacteria ascending from the vagina into the uterus. The cervix normally produces antimicrobial peptides like defensins to block this. By delivering extra defensin genes to the cervix, researchers can boost this natural barrier.
Is this ready for use in humans?
No — this is an early animal study. It proves the concept works in mice, but extensive safety testing would be needed before considering human trials, especially given concerns about gene therapy during pregnancy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05150APA
Suff, Natalie; Karda, Rajvinder; Diaz, Juan Antinao; Ng, Joanne; Baruteau, Julien; Perocheau, Dany; Taylor, Peter W; Alber, Dagmar; Buckley, Suzanne M K; Bajaj-Elliott, Mona; Waddington, Simon N; Peebles, Donald. (2020). Cervical Gene Delivery of the Antimicrobial Peptide, Human β-Defensin (HBD)-3, in a Mouse Model of Ascending Infection-Related Preterm Birth.. Frontiers in immunology, 11, 106. https://doi.org/10.3389/fimmu.2020.00106
MLA
Suff, Natalie, et al. "Cervical Gene Delivery of the Antimicrobial Peptide, Human β-Defensin (HBD)-3, in a Mouse Model of Ascending Infection-Related Preterm Birth.." Frontiers in immunology, 2020. https://doi.org/10.3389/fimmu.2020.00106
RethinkPeptides
RethinkPeptides Research Database. "Cervical Gene Delivery of the Antimicrobial Peptide, Human β..." RPEP-05150. Retrieved from https://rethinkpeptides.com/research/suff-2020-cervical-gene-delivery-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.